Insilico Biotechnology AG delivers predictive Digital Twins for the biopharmaceutical industry. Insilico Digital Twins lead to superior productivity, product quality and process robustness by using artificial intelligence and mechanistic knowledge. As a result, Insilico's unique approach substantially reduces costs of manufacturing and time to market. Leading biopharmaceutical companies worldwide use Insilico Digital Twins for process development and manufacturing of drugs. Founded in 2001, Insilico Biotechnology is a privately held company based in Stuttgart, Germany.